← Patent-cliff monitor small molecule UKONIQ UMBRALISIB TOSYLATE
Loss of exclusivity May 2035 latest FDA-listed patent expiry
Drug detail Brand name UKONIQ Active ingredient UMBRALISIB TOSYLATE Strength EQ 200MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval February 2021 Marketing status DISCN
Listed patents Patent Expires Type 10947244 May 2035 use U-3064 10414773 May 2035 substance, product 9969740 May 2035 substance, product 10981919 July 2033 use U-3064 10072013 July 2033 use U-3064 9150579 July 2033 substance, product 10570142 July 2033 substance, product 9669033 July 2033 use U-3064
Regulatory exclusivity Code Expires NCE February 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.